en · de · es · fr · pt
selank-notes.peptides6088.com › Guide › Mechanism And Evidence Status — Beginner to Advanced

Mechanism And Evidence Status — Beginner to Advanced

By Editorial Desk · published 2025-10-08 · last reviewed 2025-11-18 · Guide

This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank at a glance

PropertyValueNotes
Primary route studiedIntranasalAlso examined parenterally in animal work
Reported plasma half-lifeMinutes to tens of minutesValues vary widely between reports
Main model systemsRodent behavioural and cell assaysHuman trials are few and small
Principal proposed targetsGABA-A receptor, GABA transaminaseMonoamine and neurotrophic pathways also reported
Evidence gradePreliminaryLimited independent replication

Selank Background And Chemical Identity

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Related pages on this site

Analytical Methods and Handling

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Background from the literature

== Redistribution == Highly lipid-soluble drugs given by intravenous or inhalation methods are initially distributed to organs with high blood flow. Later, less vascular but more bulky tissues (such as muscle and fat) take up the drug—plasma concentration falls and the drug is withdrawn from these sites. If the site of action of the drug was in one of the highly perfused organs, redistribution results in termination of the drug action. The greater the lipid solubility of the drug, the faster its redistribution will be. For example, the anaesthetic action of thiopentone is terminated in a few minutes due to redistribution. However, when the same drug is given repeatedly or continuously over long periods, the low-perfusion and high-capacity sites are progressively filled up and the drug becomes longer-acting.

=== SGLT inhibition === McGuire is known for his research on sodium-glucose cotransporter-2 (SGLT2) and SGLT1/2 inhibitors. McGuire has had consultancy and/or trial leadership roles for all SGLT inhibitors presently available for clinical use in the US, and he has contributed to iterative meta-analyses of randomized CVOT trials data on SGLT2 and SGLT1/2 inhibitors. These analyses found that SGLT inhibitors reduce the risk of MACE, hospitalization for heart failure, and progression of chronic kidney disease. The benefits were consistent across patients with and without type 2 diabetes and across varying levels of cardiovascular and kidney risk.

=== 2010s === In 2010, Grace received approval from the U.S. Bankruptcy Court for the merger with Synthetec, which is a company that had developed and manufactured amino acid and peptide products as well as proprietary custom chiral intermediates primarily for the pharmaceutical industry. In 2014, the Grace bankruptcy process terminated. However, some legal procedures continued into the next decade. In February 2016, Grace completed the corporate spin-off of GCP Applied Technologies, which was also as a public trading corporation on the NYSE. Grace shareholders receive GCP stock on 1:1 ratio. GCP Applied Technologies consisted of the concrete admixture and related products company Grace Construction Products (GCP) and Darex, a packaging technologies business unit. In July 2016, Grace acquired the global polyolefin catalysts business unit from BASF.

Sources: en.wikipedia.org

Reference notes

== Instrumentation == The CI source design for a mass spectrometer is very similar to that of the EI source. To facilitate the reactions between the ions and molecules, the chamber is kept relatively gas tight at a pressure of about 1 torr. Electrons are produced externally to the source volume (at a lower pressure of 10−4 torr or below) by heating a metal filament which is made of tungsten, rhenium, or iridium. The electrons are introduced through a small aperture in the source wall at energies 200–1000 eV so that they penetrate to at least the centre of the box. In contrast to EI, the magnet and the electron trap are not needed for CI, since the electrons do not travel to the end of the chamber. Many modern sources are dual or combination EI/CI sources and can be switched from EI mode to CI mode and back in seconds.

Anders Ericsson of Florida State University did not believe that sufficient evidence existed to suggest that the skills of Price and another documented case, Brad Williams, needed additional explanation: "Our work has pretty much concluded that differences in memory don't seem to be the result of innate differences, but more the kinds of skills that are developed." As the condition has become better known, more people claiming to have hyperthymestic abilities have emerged. In the aftermath of the 2006 Neurocase publication alone, more than 200 people contacted McGaugh; however, only a handful of cases were determined to be actual cases of hyperthymesia. The second verified case was Brad Williams, the third was Rick Baron, and in 2009, Bob Petrella became the fourth person diagnosed with hyperthymestic syndrome. The U.S. television program 60 Minutes featured actress Marilu Henner in 2010 for her superior autobiographical memory ability. Henner claimed to remember almost every day of her life since age 11. The show was initially pitched as a story featuring hyperthymestic violinist Louise Owen, but the reporter Lesley Stahl volunteered her friend Henner as having a similar ability. In 2012, reports emerged of H.K. Derryberry, a blind 20-year-old man who could clearly recall every day of the last nine years of his life. Derryberry had been born at 27 weeks, weighing just over 2 pounds (0.91 kg) and was in neonatal intensive care for 96 days. A brain hemorrhage was the likely cause of cerebral palsy, and his premature birth brought congenital blindness.

This means the rule must be pursue a legitimate aim and (1) be suitable to achieve the aim, (2) be necessary, so that a less restrictive measure could not achieve the same result, and (3) be reasonable in balancing the interests of free trade with interests in article 36.

Ultimately, the only physical mobilites that Eastlack had left were that of his face (his eyebrows, eyes, ears, nose, cheeks, and lips), his tongue, and partially his teeth and jaw, although this was extremely restricted. As the disease progressed and his bones ossified and he became more immobilized, Eastlack struggled more with routine movement and self-care. His family (especially his mother) would take care of him, but when she could no longer continue taking care of him as she grew older, Eastlack was then taken to a nursing home in Philadelphia, The Inglis House for the Incurables, which is now simply known as the Inglis House.

Sources: en.wikipedia.org

Notes from published material

=== Ceasefire attempts === Syrian minister of defense Murhaf Abu Qasra announced a ceasefire effective from 15 July 2025 after an agreement with the Druze leaders in Suwayda. The Syrian Ministry of Interior warned against any damage to private or public property in Suwayda. According to the ceasefire agreement, it was not a complete withdrawal of the administration, and it would be able to continue to maintain police forces in the district, which would operate together with local Druze, but it was required, as stated, to withdraw the military forces it had sent there in the battles in recent days. A mechanism was also agreed upon to regulate the issue of possession of heavy weapons in the area. The agreement also stipulates the establishment of an investigative committee that will examine atrocities committed by militants and regime members against the Druze, according to reports. Following the second ceasefire announced on 16 July 2025, Syrian president Ahmed al-Sharaa addressed the nation stating that the government's priority is to protect Druze citizens as Israel continues its assaults on Syria. He further said "we reject any attempt to drag you into hands of an external party. We are not among those who fear the war. We have spent our lives facing challenges and defending our people, but we have put the interests of the Syrians before chaos and destruction".

== Limitations == The cytocentrifugation process can cause cells to appear distorted. Cells located at the centre of the smear may look compressed compared to cells at the periphery. Cell nuclei may develop artifactual clefts, lobes, or holes, and the cytoplasm may appear vacuolated or develop irregular projections. Cytoplasmic granules may be pushed to the periphery of the cell. If the cell count is high, cells may be distorted due to crowding; therefore, samples with high cell counts are diluted prior to smear preparation.

== External links == A more advanced video detailing the different types of post-translational modifications and their chemical structures A useful video visualising the process of converting DNA to protein via transcription and translation Video visualising the process of protein folding from the non-functional primary structure to a mature, folded 3D protein structure with reference to the role of mutations and protein mis-folding in disease

Successful delivery of therapeutics to the intended target largely depends on the choice of the drug carrier. The criteria for an ideal drug carrier include maximum effect upon delivery of the drug to the target organ, evasion of the immune system of the body in the process of reaching the organ, retention of the therapeutic molecules from preparatory stages to the final delivery of the drug, and proper release of the drug for exertion of the intended therapeutic effect. Nanofibers are under study as a possible drug carrier candidate. Natural polymers such as gelatin and alginate make for good fabrication biomaterials for carrier nanofibers because of their biocompatibility and biodegradability that result in no harm to the tissue of the host and no toxic accumulation in the human body, respectively. Due to their cylindrical morphology, nanofibers possess a high surface area-to-volume ratio. As a result, the fibers possess high drug-loading capacity and may release therapeutic molecules over a large surface area. Whereas surface area to volume ratio can only be controlled by adjusting the radius for spherical vesicles, nanofibers have more degrees of freedom in controlling the ratio by varying both the length and the cross-sectional radius. This adjustability is important for their application in drug delivery system in which the functional parameters need to be precisely controlled. Preliminary studies indicate that antibiotics and anticancer drugs may be encapsulated in electrospun nanofibers by adding the drug into the polymer solution prior to electrospinning.

=== Keratin-like characteristics === Spongin also exhibits compositional similarities to keratin, particularly in its sulfur content and thermal stability. It withstands temperatures up to 300 °C, which is more characteristic for keratin than collagen. However, due to spongin's distinct biochemical features, its full molecular classification remains unknown.

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

What happens to Selank after intranasal dosing?

The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.

How strong is the clinical evidence?

Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

Network